There is new hope for Glioblastoma (GBM) patients from a class of chemotherapy drugs called anti-angiogenic compounds, which are designed to block the growth of new blood vessels in a tumor. The original findings of two large clinical trials showed that lives of GBM patients were not extended by the treatment. A new study at Stanford further analyzed these findings and have drawn a conclusion that this particular therapy has extended the lives of certain patients by about a year compared to similar patients who took chemotherapy.
These results have shown how different GBM can be from one patient to the next. The researchers are hoping that this conclusion will begin to open the thinking and research to other therapy options that might be lifesaving.
To read the full article, click here.